Evidence map›Paper›PMID 42171260›Full record

ArticleAnalytical methods : advancing methods and applications2026

Simultaneous measurement of piperacillin, tazobactam and meropenem in patient samples using LC-MS/MS to support β-lactam therapeutic drug monitoring.

Stefania Federico, Suzy Williams, Richard C Wilson, Paul Arkel, Mark J Gilchrist, Alison H Holmes, Timothy M Rawson, Alaa Riezk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical methods : advancing methods and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stefania FedericoCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Suzy WilliamsCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Richard C WilsonCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Paul ArkelCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Mark J GilchristCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Alison H HolmesCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Timothy M RawsonCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.
Alaa RiezkCentre for Antimicrobial Optimisation, Imperial College London, London, UK. alaa.riezk@imperial.ac.uk.ORCID 0000-0002-1829-5770

Funding

Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial Agentsbeta-LactamsDrug MonitoringLiquid Chromatography-Mass SpectrometryMeropenemPiperacillinTandem Mass Spectrometrybeta Lactam AntibioticsChromatography, LiquidHumansLimit of DetectionPenicillanic AcidReproducibility of ResultsTazobactamThienamycinsAnti-Bacterial Agentsbeta Lactam Antibioticsbeta-LactamsMeropenemPenicillanic AcidPiperacillinTazobactamThienamycins

Identifiers

PMID42171260
PMCPMC13195413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.